怡道生物科技

Yidao Biotech is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative recombinant vaccines. The company's lead candidate, YD-V01, is a recombinant herpes zoster (shingles) vaccine currently in Phase 3 clinical trials, designed to offer high efficacy and safety comparable to international standards. Beyond shingles, Yidao Biotech is advancing a pipeline that includes multi-valent human papillomavirus (HPV) vaccines and other recombinant protein-based biologics. Founded by industry veterans with extensive experience in global vaccine development, the company leverages advanced adjuvant technologies and protein expression systems to address significant unmet needs in infectious disease prevention.